Company news

Sangamo Therapeutics, Inc. news in 2024

Sangamo Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Sangamo Therapeutics to Regain Full Rights to Hemophilia A Gene Therapy Program Following Pfizer’s Decision to Cease Development of Giroctocogene Fitelparvovec

December 29, 2024

Sangamo Therapeutics and Astellas Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

December 18, 2024

Astellas and Sangamo Therapeutics Announce Capsid License Agreement to Deliver Genomic Medicines for Neurological Diseases

December 18, 2024

Sangamo Therapeutics Announces U.S. FDA Clearance of IND Application for ST-503 for the Treatment of Idiopathic Small Fiber Neuropathy, a Type of Chronic Neuropathic Pain

November 18, 2024

Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2024 Financial Results

November 11, 2024

Sangamo Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

November 3, 2024

Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025

October 21, 2024

Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2024 Financial Results

August 5, 2024

Sangamo Therapeutics Announces Global Epigenetic Regulation and Capsid Delivery License Agreement with Genentech to Develop Novel Genomic Medicines for Neurodegenerative Diseases

August 5, 2024

Sangamo Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

July 29, 2024

Sangamo Therapeutics Reports on Pfizer’s Announcement of Positive Topline Results From Phase 3 Trial of Hemophilia A Gene Therapy Candidate

July 23, 2024

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

May 8, 2024

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

May 8, 2024

Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast

May 1, 2024

Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)

April 21, 2024

Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering

March 21, 2024

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

March 12, 2024

Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs

March 12, 2024

Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast

March 11, 2024

Sangamo Therapeutics Announces U.S. FDA Alignment on Abbreviated Pathway to Potential Approval and EMA Prime Eligibility for ST-920 in Fabry Disease

February 11, 2024

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

February 4, 2024

Calls in 2024

Decks in 2024